5.26
Monte Rosa Therapeutics Inc stock is traded at $5.26, with a volume of 371.65K.
It is down -5.23% in the last 24 hours and up +14.35% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$5.55
Open:
$5.6
24h Volume:
371.65K
Relative Volume:
0.87
Market Cap:
$323.54M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.3482
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
-7.07%
1M Performance:
+14.35%
6M Performance:
-12.19%
1Y Performance:
+15.10%
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GLUE
Monte Rosa Therapeutics Inc
|
5.26 | 341.38M | 0 | -130.41M | -67.76M | -2.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-15-24 | Initiated | Wedbush | Outperform |
Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-13-22 | Initiated | UBS | Buy |
Aug-15-22 | Initiated | Jefferies | Buy |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Will Monte Rosa Therapeutics Inc. bounce back from current supportSwing Candidate List with Trade Cues - Newser
Sector ETF performance correlation with Monte Rosa Therapeutics Inc.Free Capital Protection Trading Strategies - Newser
Can Monte Rosa Therapeutics Inc. Regain Lost Ground This QuarterLow Risk High Return Opportunities Identified - metal.it
Real time scanner hits for Monte Rosa Therapeutics Inc. explainedPredictive Screener for Daily Trade Watch - Newser
What makes Monte Rosa Therapeutics Inc. stock price move sharplyFree Stock Target Finder That Work - jammulinksnews.com
Should you hold or exit Monte Rosa Therapeutics Inc. nowMonthly Long-Term Market Recap and Summary - Newser
Sector ETF performance correlation with Monte Rosa Therapeutics Inc. Daily Entry Opportunity Forecasting Tool - Newser
Monte Rosa Therapeutics Inc. Enters Reversal Setup in Weekly ChartsReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Real time scanner hits for Monte Rosa Therapeutics Inc. explained Chart Pattern Recognition for Profit Timing - Newser
What institutional investors are buying Monte Rosa Therapeutics Inc. stockConsistent wealth multiplication - jammulinksnews.com
Is Monte Rosa Therapeutics Inc. a Top Dividend Stock to Watch in 2025Consistent Win Signals - metal.it
How does Monte Rosa Therapeutics Inc. generate profit in a changing economyMaximize gains with strategic stock entries - jammulinksnews.com
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention Free Accurate Buy Point for Momentum Stocks - Newser
What are the technical indicators suggesting about Monte Rosa Therapeutics Inc.Consistent high-yield stocks - jammulinksnews.com
What are the latest earnings results for Monte Rosa Therapeutics Inc.High-return market picks - jammulinksnews.com
How strong is Monte Rosa Therapeutics Inc. company’s balance sheetRemarkably fast returns - jammulinksnews.com
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attentionFree Financial Group - Newser
How Monte Rosa Therapeutics Inc. stock performs during market volatilityFree Access to Community - Newser
What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional
What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader By Investing.com - Investing.com South Africa
First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):